AP NEWS

Covalon Announces Issuance of Stock Options

September 28, 2018

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Sep 28, 2018--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV:COV.V)(OTCQX:CVALF), an advanced medical technologies company, today announced the issuance of an aggregate of 155,000 stock options to directors, officers and staff of the Company. The stock options will vest over three years and will be exercisable for a period of five years at an exercise price of $8.50 per stock option.

About Covalon

Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon’s patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon’s technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan, “estimate”, “expect”, “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company’s ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005214/en/

CONTACT: Brian Pedlar, CEO, Covalon Technologies Ltd.

Email:bpedlar@covalon.com

Phone: 905.568.8400 x 233

Toll free: 1.877.711.6055

Web site:www.covalon.com

Twitter: @covalon

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: SURGERY HEALTH CARDIOLOGY HOSPITALS INFECTIOUS DISEASES MEDICAL DEVICES GENERAL HEALTH

SOURCE: Covalon Technologies Ltd.

Copyright Business Wire 2018.

PUB: 09/28/2018 08:00 AM/DISC: 09/28/2018 08:01 AM

http://www.businesswire.com/news/home/20180928005214/en

AP RADIO
Update hourly